Cingulate Inc. filings document a clinical-stage biopharmaceutical issuer developing Precision Timed Release™ drug-delivery products, including CTx-1301 for ADHD, alongside its common stock and warrants listed on Nasdaq. Periodic and current reports furnish operating results, business updates, patent notices, FDA-related program disclosures and research-and-development spending context.
The filing record also covers capital-structure actions such as private placements, preferred stock, warrants, unregistered equity issuances, debt exchanges and at-the-market offering agreements. Proxy and 8-K disclosures address shareholder voting matters, Nasdaq rule compliance, board committee composition, officer appointments, employment agreements and other governance events.
Cingulate Inc. reported a larger net loss for the quarter ended March 31, 2026 as it funds late‑stage ADHD development and commercial preparation. Net loss widened to $9.3 million from $3.9 million a year earlier, with general and administrative costs rising sharply to $5.7 million as the company ramped pre‑commercialization spending for lead candidate CTx‑1301.
Research and development expenses were stable at about $2.2 million, reflecting a shift from clinical operations toward manufacturing and regulatory work ahead of potential approval. Cash and cash equivalents increased to $25.9 million, driven by equity raises, including a ~$12 million private placement, ATM sales and an equity line with Lincoln Park.
The company ended the quarter with $18.9 million of stockholders’ equity and $12.0 million in total liabilities, including a $6.1 million Avondale promissory note. Management believes current cash can fund operations into early 2027 but discloses substantial doubt about its ability to continue as a going concern without additional capital and successful FDA approval and commercialization of CTx‑1301.
Cingulate Inc. reported first quarter 2026 results and highlighted progress toward launching its lead ADHD drug candidate, CTx-1301. Cash and cash equivalents were $25.9 million as of March 31, 2026, up $14.9 million from year-end, largely from a $12.0 million private placement and use of at-the-market and stock purchase agreements. Working capital rose to $17.0 million, and total stockholders’ equity increased to $18.9 million from $2.5 million.
R&D expenses were $2.2 million, down 1.8% year over year as clinical studies wound down, while general and administrative expenses rose to $5.7 million from $1.5 million, reflecting commercial infrastructure build-out for CTx-1301. Net loss widened to $9.3 million from $3.9 million, driven mainly by higher G&A and changes in derivative fair value and interest expense.
The FDA is reviewing the New Drug Application for CTx-1301, with a PDUFA target action date of May 31, 2026. Cingulate continues to respond to manufacturing and CMC information requests while preparing for commercialization, including AI-enabled marketing, payer and distribution planning, manufacturing scale-up, and a sales-force agreement with IQVIA. Management believes current resources support operations into 2027.
Cingulate Inc. reported that EVP and CSO Raul R. Silva received a grant of stock options covering 3,422 shares of common stock. The options have an exercise price of $6.21 per share, were granted at no purchase cost, and expire on March 31, 2036. The award was made pursuant to Dr. Silva's Employment Agreement, as amended, and reflects equity-based compensation rather than an open-market share purchase or sale.
Cingulate Inc. is registering up to 4,208,711 shares of its common stock for resale by selling stockholders. The shares consist of (i) 2,147,472 issued common shares, (ii) 191,824 shares issued upon conversion of Preferred Stock, and (iii) 1,869,415 shares issuable upon exercise of a warrant. The company will receive no proceeds from resales by the selling stockholders; however, cash exercise of the warrant could yield approximately $9.4 million to the company. The prospectus discloses a Private Placement that raised approximately $12.0 million in aggregate gross proceeds and includes standard lock-up and standstill provisions for the purchasers.
Cingulate Inc. registers up to 4,208,711 shares of common stock for resale by selling stockholders. The registration covers shares issued in a January 27, 2026 private placement, consisting of 2,147,472 issued common shares, 191,824 shares issued upon conversion of Preferred Stock and 1,869,415 shares issuable upon exercise of a warrant.
The company will receive no proceeds from resales by the selling stockholders; however, if the warrant is exercised for cash in full, Cingulate would receive approximately $9.4 million, which it intends to use for regulatory approval and development, manufacturing and commercialization of CTx-1301 and for general corporate purposes.
Cingulate Inc. registers for resale up to 3,500,000 additional shares of common stock to be offered by Lincoln Park Capital Fund, LLC under a purchase agreement providing up to $25.0 million of committed equity financing.
The registration covers shares the company may elect to issue and sell to Lincoln Park under a July 21, 2025 Purchase Agreement; the company will control timing and may receive proceeds only if it sells Purchase Shares to Lincoln Park. Shares outstanding were 11,594,679 as of March 13, 2026; the prospectus shows an illustrative post-issuance count of 15,094,679 assuming sale of all 3,500,000 additional shares.
Falcon Creek Capital Advisor LLC and related funds filed an amended beneficial ownership report on Cingulate Inc. common stock after acquiring shares on 03/24/2026 under a Purchase Agreement. Falcon Creek Capital Advisor reports beneficial ownership of 3,856,766 shares, representing 28.50% of Cingulate’s common stock, with shared voting and dispositive power over all such shares. Falcon Creek Technology Fund I holds 350,195 shares, or 2.59%, and Ginkgo Capital Global Fund SPC – Xtalpi AI Fund holds 3,506,571 shares, or 25.91%, each with shared voting and dispositive power. The reporting persons describe their holdings as venture and investment positions and state that, aside from the Purchase Agreement and related arrangements, they have no other contracts or understandings concerning Cingulate’s securities.
Cingulate Inc. is registering common stock with an aggregate offering price of $100,000,000 for sale at-the-market through A.G.P./Alliance Global Partners pursuant to an At The Market Sales Agreement dated March 24, 2026.
The prospectus supplement states sales may be made on Nasdaq or other U.S. trading markets, A.G.P. will act as sales agent (entitled to a 3.0% commission) and the company intends to use net proceeds to advance CTx-1301 regulatory, development, manufacturing and commercialization activities and for general corporate purposes.